Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatrics ; 112(1 Pt 1): 96-100, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12837873

ABSTRACT

OBJECTIVE: Fluticasone propionate aqueous nasal spray (FP) at the highest recommended doses does not affect hypothalamic-pituitary-adrenal (HPA) axis function in adults or older children, but its potential effects in children younger than 4 years have not been previously studied. This randomized, double-blind, placebo-controlled study evaluated the effects of FP on HPA axis function measured by 12-hour urinary-free cortisol levels in children 2 to 3 years of age. METHODS: Patients ages 2 to 3 years with symptoms of allergic rhinitis were administered FP 200 microg/day (FP200 QD) or vehicle placebo for 6 weeks. RESULTS: The FP200 QD group (n = 33) was equivalent to the placebo group (n = 32) in mean change from baseline in the primary safety measure of 12-hour creatinine-corrected urinary-free cortisol concentration (geometric mean difference [standard error; SE] for placebo-FP200 QD = 0.96 [1.20]; 95% confidence interval 0.66, 1.39) at the end of the treatment period. The adjusted geometric mean change from baseline value was 0.98 for FP200 QD (SE = 1.14) and 0.94 for placebo (SE = 1.15); a value of 1.0 reflects no change from baseline. Cough and fever were the most common adverse events reported in either group. CONCLUSIONS: FP200 QD was equivalent to placebo with respect to effects on HPA axis function measured by 12-hour urinary-free cortisol in 2- and 3-year-old patients. FP200 QD was well-tolerated in these very young children with allergic rhinitis.


Subject(s)
Androstadienes/pharmacology , Anti-Allergic Agents/pharmacology , Hypothalamo-Hypophyseal System/drug effects , Administration, Intranasal , Androstadienes/administration & dosage , Androstadienes/adverse effects , Anti-Allergic Agents/administration & dosage , Anti-Allergic Agents/adverse effects , Child, Preschool , Double-Blind Method , Female , Fluticasone , Humans , Hydrocortisone/metabolism , Hydrocortisone/urine , Male , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Perennial/urine , Rhinitis, Allergic, Seasonal/drug therapy , Rhinitis, Allergic, Seasonal/urine
2.
Allergy Asthma Proc ; 23(4): 259-63, 2002.
Article in English | MEDLINE | ID: mdl-12221896

ABSTRACT

Although allergic rhinitis is commonly associated most with symptoms of nasal congestion, rhinorrhea, sneezing, and itching, the symptom of sinus pain and pressure often prompts the patient to seek medical attention. The effect of fluticasone propionate on this symptom has not been studied. The purpose of this study was to compare the efficacy and safety of fluticasone propionate aqueous nasal spray to placebo vehicle in the treatment of patients with sinus pain and pressure arising from allergic rhinitis. A multicenter, double-blind, parallel-group trial was conducted in 206 symptomatic patients > or = 12 years with seasonal or perennial allergic rhinitis. Patients were treated for 14 days with either fluticasone propionate aqueous nasal spray, 200 mcg once daily, or placebo vehicle. Patients attended clinic visits and kept diary cards rating sinus pain and pressure (measured as one symptom) and nasal congestion symptoms during the study. Treatment with fluticasone propionate provided significantly greater relief of symptoms of sinus pain and pressure compared with placebo over the entire 14-day treatment period. Nasal congestion scores also were significantly reduced compared with placebo at each time point. Treatments were well tolerated, and the incidence of adverse events attributable to study treatments was similar between groups. Our data indicate that symptoms of sinus pain and pressure and nasal congestion can be significantly reduced in patients with allergic rhinitis when treated with fluticasone propionate aqueous nasal spray, 200 mcg once daily.


Subject(s)
Androstadienes/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Facial Pain/drug therapy , Paranasal Sinuses/drug effects , Paranasal Sinuses/pathology , Administration, Topical , Adolescent , Adult , Aged , Androstadienes/adverse effects , Anti-Inflammatory Agents/adverse effects , Child , Double-Blind Method , Drug Evaluation , Facial Pain/etiology , Female , Fluticasone , Glucocorticoids , Humans , Male , Middle Aged , Rhinitis, Allergic, Perennial/complications , Rhinitis, Allergic, Perennial/drug therapy , Treatment Outcome , United States/epidemiology , Withholding Treatment
SELECTION OF CITATIONS
SEARCH DETAIL
...